The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.

TD Cowen analyst Daniel Brennan maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $140.00. The ...

Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

The Trump administration has announced a variety of trade actions including tariffs and other measures that could impact U.S.

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Shares of Illumina Inc. ILMN rose 2.33% to $86.62 Friday, on what proved to be an all-around positive trading session for the ...